EIT Health Innovation Uptake Call 2026: Up to €650,000 for Digital, Data-Driven and AI Healthcare Solutions

EIT Health Innovation Uptake Call 2026: Up to €650,000 for Digital, Data-Driven and AI Healthcare Solutions

The EIT Health Innovation Uptake Call 2026 is aimed at healthcare innovators who have moved beyond an interesting prototype and now need evidence, market access work, and real-world implementation. EIT Health is seeking mature digital, data-driven, and artificial-intelligence-powered healthcare solutions that are ready to scale across European markets. The call can support up to eight projects, with a total budget of up to €5.2 million and a maximum grant of €650,000 per project.

The call opened on 24 June 2026. The application deadline is 16 September 2026 at 16:00 CET. This is a consortium call, not an individual fellowship or a solo-founder award. A proposal must bring together at least two independent legal entities from different countries, represent at least two sides of the Industry, Research, and Education Knowledge Triangle, and be led by a commercialising entity such as an SME or industry player. EIT Health describes that lead as the organisation responsible for bringing the solution to market.

This page explains what the opportunity actually funds, the profile it suits, the evidence a serious consortium should assemble, and the limits that remain unclear in the public opportunity summary. Read the current call document and supporting documents before submitting: the public summary gives the core conditions, but it does not publish every technical application rule in the page text.

Key details

What the call offers

The grant is designed for the difficult middle stage between technical readiness and routine adoption. A healthcare product may work in a controlled setting yet still lack the clinical, economic, operational, or reimbursement evidence that hospitals and health systems need before they will adopt it. The Innovation Uptake Call is structured around that gap.

EIT Health identifies five kinds of work that fit the call. Projects may run commercialisation pilots in real-world healthcare settings. They may test usability and adapt a product for a new market. They may validate a go-to-market strategy or business model. They may carry out health economics analysis. They may develop a reimbursement pathway. These are practical adoption activities, not a general-purpose research budget.

The financial headline needs careful reading. The maximum grant is €650,000, but the grant covers up to 50% of total project costs, so a consortium must provide the remaining project financing. An SME leading the project receives €400,000–€500,000 within the grant according to the public EIT Health summary. That range is not a promise that every SME-led proposal will receive that amount; it sits inside the overall award ceiling and must still be supported by an eligible work plan and budget.

The public page says that up to eight projects will be funded. It does not state that every eligible proposal will receive funding, nor does it publish a guaranteed minimum award. Treat the €650,000 figure as a ceiling for planning, not as an entitlement.

What kind of healthcare innovation fits

The call is for solutions that are mature enough to be used, tested, or commercialised in actual healthcare environments. The official description does not provide a single exhaustive product list. It does, however, consistently frames the opportunity around digital, data-driven, and AI-powered healthcare and around adoption across European markets.

A credible fit might be a clinical software product that needs deployment evidence in hospitals, a data-driven tool that requires validation with health-system partners, or an AI-enabled service that must adapt to workflows and market requirements in more than one country. The proposal should be able to explain not just what the product does, but what prevents a buyer, provider, payer, or health authority from adopting it today.

The distinction between development and uptake matters. If the central task is still proving that the underlying technology works at all, the consortium may be too early for this call. If the product is clinically validated but cannot yet cross the operational barriers to adoption, the fit is stronger. Product usability testing, health economic work, and reimbursement planning can each be a legitimate bridge from a validated solution to a deployable one.

EIT Health also lists expected outcomes that should shape the proposal. Funded projects are expected to launch the innovation to market with at least €10,000 in revenue within one year after the project, reach at least 150,000 patients or citizens within three years, generate strong clinical, economic, and commercial evidence, and demonstrate scalable and sustainable deployment models across European markets. These are unusually concrete signals about the level of ambition expected.

Who is eligible to apply

Individuals cannot apply. The applicant must be a consortium of legal entities, with at least two independent legal entities from different countries. The entities must be established in eligible Horizon Europe countries, which the EIT page describes as EU Member States, associated countries, or eligible third countries. The public summary does not enumerate every eligible country, so a proposed partner should verify its country status in the current call documents and portal before the consortium is finalised.

The consortium must represent at least two sides of the Knowledge Triangle: Industry, Research, and Education. The lead must be a commercialising entity, specifically an SME or industry player that is responsible for bringing the solution to market. A university or research organisation may be an important partner, but a consortium led by research without a credible commercialising lead would not match the stated structure.

The call therefore suits a company that already has a defined route to market and needs partners to prove adoption, rather than a team seeking open-ended discovery funding. It can also suit a research or education partner that has a mature healthcare innovation and can contribute the evidence, implementation, or evaluation capacity required for commercialisation. Each partner should have a distinct job in the adoption plan. Adding institutions only to satisfy a consortium rule can make a proposal look assembled rather than operational.

How the application works

EIT Health gives a two-step starting process. First, each organisation should register in the EU Funding & Tenders Portal and obtain a nine-digit Participant Identification Code, commonly called a PIC number. If an organisation may already have one, the EIT Health page directs applicants to check the EU portal rather than creating a duplicate registration.

Second, the consortium applies through EIT Health’s application platform. The public opportunity page says that the platform opened on 15 July 2026. The live submission route and the current call document should be treated as the controlling sources for the final form, attachments, budget fields, and any declarations.

The public summary does not list a complete set of required attachments in its page text. That is a meaningful unknown, not a reason to improvise. Before drafting the final version, download and read the official call document and supporting documents linked from the EIT Health page. Confirm whether the platform requires partner descriptions, financial information, work packages, implementation evidence, clinical validation, market analysis, risk registers, co-funding declarations, or other annexes. Leave time for portal registration and partner verification rather than treating those as last-minute administration.

Timeline and deadline

The call opened on 24 June 2026, and the application platform became available on 15 July 2026. EIT Health held an information session on 15 July and scheduled an open question-and-answer session for 1 September 2026. The deadline is 16 September 2026 at 16:00 CET.

The deadline should be converted carefully for every partner. A consortium spread across Europe may be working in different local time zones, and portal traffic or an incomplete participant record can create a problem close to the cutoff. The official EIT opportunity page gives 16:00 CET; check how the application platform displays the closing time after logging in and submit before the final day if possible.

The public page does not state the date for evaluation results, grant agreement preparation, or project start. Do not promise a launch date, award notification date, or project duration in a public-facing plan unless the current call document confirms it. Those details should be verified directly in the official supporting material.

What to prepare before writing

Start with an adoption obstacle, not a product description. Write one sentence identifying the healthcare setting, the user or buyer, the evidence gap, and the decision that the project is intended to change. For example, a consortium might need to show that a validated tool can be integrated into clinical workflows, produce reliable health-economic evidence, and satisfy a reimbursement process in more than one market. The exact example will depend on the product; the principle is to connect the grant activities to an adoption decision.

Confirm the consortium architecture early. Record each partner’s country, legal-entity status, Knowledge Triangle role, contribution, and responsibility for market or evidence work. Identify the commercialising lead explicitly. If the lead cannot explain who will sell, deploy, or contract for the solution after the project, the commercialisation claim is incomplete.

Build the co-funding model before setting the grant request. A €650,000 grant at 50% funding intensity implies a project with at least €1.3 million in eligible total costs, subject to the rules in the call documents. That is a planning calculation, not a confirmed budget formula for every cost category. Show where the non-grant share comes from, which partner carries it, and what happens if the award is smaller than requested. A budget that depends on uncommitted money is a material execution risk.

Then map the work to measurable outcomes. The public targets — at least €10,000 in revenue within one year after the project and at least 150,000 patients or citizens within three years — should be treated as tests of commercial and social scale. Explain the baseline, the route to the target, the markets involved, and the evidence that will be collected. Avoid claiming that a large addressable market automatically equals reach. Reviewers need a credible deployment path.

Evidence and reviewer expectations

The official summary points toward clinical, economic, and commercial evidence. A strong proposal should make those three kinds of evidence reinforce one another. Clinical or performance evidence can establish that the solution works for its intended use. Economic evidence can show whether it improves outcomes, reduces cost, saves staff time, or otherwise creates value for a health system. Commercial evidence can show that a defined customer, channel, and reimbursement or procurement route exists.

The work plan should also show why the chosen partner countries and healthcare settings matter. A pilot in one setting is not automatically proof of scalability across Europe. Explain which elements are common across markets and which must be adapted, such as language, workflow, data governance, reimbursement, procurement, or training. If the product depends on access to sensitive health data, identify the governance and permissions work as part of delivery rather than hiding it in a generic risk paragraph.

Do not inflate evidence quality. If a result is from a small pilot, call it a small pilot. If a market assumption has not been tested, label it as an assumption and give the experiment that will test it. The call’s emphasis on real-world evidence makes transparent measurement more persuasive than a long list of unsupported claims.

Common mistakes to avoid

The first mistake is applying as a single organisation. The official requirement is a consortium with independent legal entities from different countries, so begin partner formation before the narrative is finished.

The second is naming a commercialising lead without giving it real responsibility. The lead should own the market route and coordinate a plan that can continue after grant-funded work ends.

The third is presenting early research as uptake. The call is about mature solutions, market entry, real-world pilots, usability, health economics, and reimbursement. A proposal dominated by basic technical development may be misaligned.

The fourth is ignoring co-funding. Requesting the maximum while leaving the other 50% vague undermines feasibility. Confirm partner commitments and test the work plan against a reduced award.

The fifth is promising the headline outcomes without a route to them. Revenue of at least €10,000 within one year and reach of at least 150,000 patients or citizens within three years should be supported by customers, sites, deployment assumptions, and measurement methods.

Finally, do not rely on a saved copy of the call page. EIT Health links the current official call document and supporting documents from its opportunity page, and the application platform is the place where final instructions will be applied. Check both immediately before submission.

Frequently asked questions

Can an individual founder apply?

No. EIT Health says applicants must be legal entities and the call requires a consortium. An individual would need to participate through an eligible organisation and an appropriately structured consortium.

How much funding is available?

The total call budget is up to €5.2 million. Up to eight projects may be funded, and the maximum funding per project is €650,000. Funding covers up to 50% of total project costs, so co-funding is required.

What does an SME lead receive?

EIT Health states that SMEs leading projects receive €400,000–€500,000 within the grant. This is a published allocation range, not a guaranteed award; the final amount remains subject to the proposal, budget, and call rules.

Does the project have to use artificial intelligence?

Not necessarily. The call is for mature digital, data-driven, or AI-powered healthcare solutions. AI is one of the named solution types, but the public summary does not say that every funded project must use AI.

What is the exact project duration?

It is not stated on the public opportunity summary reviewed for this guide. Confirm duration, eligible cost periods, and start-date rules in the official call document.

Where can applicants ask questions?

The EIT Health opportunity page lists an open Q&A session on 1 September 2026 and links to the official application and supporting documents. Use the current official page and portal for the latest question process.

Official links and next steps

Begin with the EIT Health Innovation Uptake Call page, which contains the call summary, eligibility outline, key dates, application route, and links to the official call documents. The European Institute of Innovation and Technology opportunity page independently confirms the funding figures, consortium structure, expected outcomes, and closing time.

If the call fits, register or verify every partner’s PIC in the EU Funding & Tenders Portal, confirm that the consortium includes the required Knowledge Triangle representation, and assign the commercialising lead’s market responsibility in writing. Next, read the current supporting documents, build the co-funded budget, and gather evidence for the clinical, economic, and commercial claims. Work backward from 16 September 2026 at 16:00 CET, leaving time for partner approval and a complete portal submission. Any requirement not stated on the public summary should be treated as unconfirmed until the official call documents or application platform provide it.